Roche says next-gen KRAS drug cut death risk 44% versus rivals

· Health · Spain

Roche presented head-to-head trial data at the ESMO congress in Madrid showing its next-generation KRAS G12C inhibitor reduced the risk of death by 44% in previously treated patients with mutant non-small cell lung cancer, compared with drugs hitting the same target from Amgen and Bristol Myers Squibb. The result gives Roche a clear efficacy edge in a crowded KRAS G12C field where several companies have launched competing inhibitors. The data was detailed during a busy Saturday at Europe's largest cancer conference, which organizers expect to draw close to 40,000 delegates over five days.

Why it matters：Head-to-head survival wins in a crowded targeted-therapy class can shift prescribing and pricing for lung cancer, pressuring Amgen and Bristol Myers Squibb to defend their KRAS franchises.

Key points

  • The trial compared Roche's drug against KRAS G12C inhibitors from Amgen and Bristol Myers Squibb.
  • Patients had previously treated mutant non-small cell lung cancer.
  • The data was presented at ESMO in Madrid.

Sources (original reporting)

More stories from this day